Treatment for Astrocytoma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Astrocytoma
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new drug for brain cancer that has progressed during first or second line treatment.

Eligible Conditions
  • Astrocytoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Randomized Perioperative Phase: Vorasidenib + Pembrolizumab
1
SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years
1
APX005M treatment for recurrent or refractory primary malignant CNS tumor patients

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: 1 year

1 year
Evaluation of the safety of NOVOTTF-200A in this subject population.
6 months
Number of participants showing no evidence of disease progression six months after initiating treatment with the device.
Month 24
Does the treatment significantly modify the patient's quality of life?
Month 24
Correlations with established molecular markers (ATRX, TERT promoter and/or IDH1 mutation and MGMT promoter methylation

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Randomized Perioperative Phase: Vorasidenib + Pembrolizumab
1
SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years
1
APX005M treatment for recurrent or refractory primary malignant CNS tumor patients

Trial Design

0 Treatment Group

34 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year

Who is running the clinical trial?

Daniela A. BotaLead Sponsor
NovoCure Ltd.Industry Sponsor
53 Previous Clinical Trials
4,560 Total Patients Enrolled
1 Trials studying Astrocytoma
1 Patients Enrolled for Astrocytoma
Daniela Bota, MDPrincipal InvestigatorUC Irvine Health
1 Previous Clinical Trials
21 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You understand and voluntarily sign and date an informed consent document before any study related assessments/procedures are conducted.
You are eligible if you have archival tumor tissue suitable for genetic testing.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top